Eledon Pharmaceuticals Inc at Ladenburg Thalmann Healthcare Conference Transcript
I'm Matt Kaplan with Ladenburg. And it's my pleasure to introduce our next presenting company, Eledon. Presenting for Eledon today is the CEO, DA Gros; and also Steve Perrin as well, the Chief Scientific Officer.
Maybe first, you can give us just a little bit of a background overview if people aren't familiar with Eledon, just a background on the company and what you're focused on.
Sure. So first, it's a pleasure to be here. Thank you very much for having invited us. We'll be -- I'd like to remind you we'll be making forward-looking statements. So please review our disclaimers in our public filings.
Eledon is focused on the development of anti-CD40 ligand antibodies. Our primary focus is around immunology. Today, our lead asset tegoprubart has completed a Phase 2 in ALS. And we have ongoing study in kidney transplantation, islet cell transplantation, and IgA Nephropathy.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |